Compare CYTK & AL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYTK | AL |
|---|---|---|
| Founded | 1997 | 2010 |
| Country | United States | United States |
| Employees | N/A | 160 |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 7.3B |
| IPO Year | 2004 | N/A |
| Metric | CYTK | AL |
|---|---|---|
| Price | $60.52 | $64.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 3 |
| Target Price | ★ $87.56 | $66.67 |
| AVG Volume (30 Days) | 1.7M | ★ 2.3M |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 1.36% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,368,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $302.66 | $5.32 |
| P/E Ratio | ★ N/A | $6.97 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $29.31 | $38.25 |
| 52 Week High | $70.98 | $64.97 |
| Indicator | CYTK | AL |
|---|---|---|
| Relative Strength Index (RSI) | 42.12 | 48.92 |
| Support Level | $59.25 | $63.38 |
| Resistance Level | $65.93 | $64.97 |
| Average True Range (ATR) | 2.76 | 0.14 |
| MACD | -0.35 | -0.04 |
| Stochastic Oscillator | 18.21 | 38.15 |
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Air Lease Corp is an aircraft leasing company based in the United States. It is engaged in the modern, fuel-efficient new technology commercial jet aircraft directly from aircraft manufacturers and leasing those aircraft to airlines throughout the world to generate attractive returns on equity. The company also sells aircraft from its fleet to third parties, including other leasing companies, financial services companies, airlines, and other investors, and offers fleet management services to investors and owners of aircraft portfolios for a management fee. Geographically, it derives a maximum of its revenue from the Europe and the rest from Asia Pacific, Middle East and Africa, Central America, South America, Mexico, the United States, and Canada.